Trial Profile
Assessment of clinical efficacy and safety in capecitabine plus intermittent oxaliplatin (intermittent CapeOx) together with Bevacizumab as the first-line therapy for patients with advanced colorectal cancer; multicenter phase II trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Feb 2018
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Oxaliplatin (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms VOICE
- 20 Jan 2018 Status changed from recruiting to completed, according to the results presented at the 2018 Gastrointestinal Cancers Symposium
- 20 Jan 2018 Primary endpoint (Progression free survival) has been met. according to the results presented at the 2018 Gastrointestinal Cancers Symposium
- 20 Jan 2018 Final results presented at the 2018 Gastrointestinal Cancers Symposium